Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 participants, all of whom completed the study — none dropped out. The trial was looking at curcumin (a compound found in turmeric) in people with a liver condition called Primary Sclerosing Cholangitis (PSC). The main thing researchers were tracking was whether a specific liver enzyme in the blood — called Serum Alkaline Phosphatase (SAP) — dropped to a certain level over 12 weeks. They also tracked several other blood markers and how tired participants felt. The reported data shows that out of the 15 participants, 3 met the target for a meaningful reduction in the SAP liver enzyme by week 12. For the secondary measures, the reported average figures at the end of the study were: an AST enzyme level (another liver marker, normally 10–40 units per litre) of 78 units per litre; a total bilirubin level (a pigment the liver processes, normally 0.3–1.9 mg/dL) of 0.6 mg/dL; a C-reactive protein level (a marker linked to inflammation, normally below 3.0 mg/L) of 3.4 mg/L; and a Mayo PSC Risk Score (a combined score used to track disease progression) of 0.54. Fatigue, measured on a scale of 0 to 84 where higher numbers mean greater fatigue, was reported at an average score of 8. It is worth noting that these figures appear to represent values at a single point in time rather than the change from the start of the study, and no comparison group (such as a placebo group) was included in this trial. The reported data does not allow conclusions about whether curcumin caused any of these results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Primary Biliary Cholangitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with primary sclerosing cholangitis (PSC), a condition that causes scarring and narrowing of the bile ducts in and/or outside the liver.
- Your blood test has shown a raised liver enzyme called alkaline phosphatase (at least 1.5 times the upper normal level) for at least 6 months before joining the study.
- An imaging scan of your bile ducts has shown changes typical of PSC, such as narrowing or irregular widening of the ducts.
- If a liver biopsy has been done, the results are consistent with or confirm a PSC diagnosis.
- If you are a woman who could become pregnant, you are willing to use contraception for the full duration of the study.
Who may not be able to join:
- You have taken part in another clinical trial or used an experimental treatment within the last 3 months, or would do so during this study.
- You have taken certain medications in the last 3 months or would need to take them during the study, including some antibiotics, steroids, or immune-suppressing drugs (confirm with trial site for the full list).
- You are currently taking anti-inflammatory painkillers (such as ibuprofen), blood thinners (such as warfarin), cholesterol-lowering drugs, or blood-clot-prevention medications.
- Your doctors expect you will need a liver transplant within the next year based on a specific PSC scoring tool.
- You are currently using recreational drugs or alcohol heavily.
- Your liver disease appears to be caused by, or is also linked to, another condition — such as hepatitis B or C, alcoholic liver disease, or another inherited or autoimmune liver condition.
- You are currently pregnant or breastfeeding.
- You have any other condition that, in the doctor's judgment, could make it unsafe or difficult for you to complete the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Serum Alkaline Phosphatase (SAP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.